PRIMARY OBJECTIVE:~I. To obtain preliminary evidence of the efficacy of elotuzumab in patients with myelofibrosis (MF) by estimating the rate of overall response by International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) 2013 criteria.~SECONDARY OBJECTIVES:~I. To characterize the safety and tolerability of elotuzumab in patients with MF.~II. To assess for improvements in cytopenias and bone marrow fibrosis grade, splenomegaly and disease-related symptoms.~III. To determine the duration of objective responses, if any, to elotuzumab. IV. To determine the time to next treatment.~EXPLORATORY OBJECTIVES:~I. To assess the proportion of circulating monocytes expressing the target of elotuzumab, SLAMF7, and any correlation of the same to the mutant JAK2 allele burden.~II. To assess baseline levels of IL-1Ralpha and other cytokines and the effects of elotuzumab, if any, on these over time.~III. To examine the effects of elotuzumab on fibrocyte count and differentiation, both in vitro and in vivo.~IV. To assess clonal evolution, if any, in MF patients on elotuzumab treatment.~OUTLINE:~Patients receive elotuzumab intravenously (IV) over 1-4 hours on days 1, 8, 15, and 22 of cycles 1-2. Beginning in cycle 3, patients receive elotuzumab IV over 1-4 hours on day 1. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed up at 30 days and then periodically thereafter.
This phase II trial investigates how well elotuzumab works in treating patients with JAK2-mutated myelofibrosis. Elotuzumab may help to control myelofibrosis and/or help to improve blood cell count and bone marrow function.